LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Pulse Biosciences Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

22.57 0.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.86

Max

22.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2M

-17M

Pardavimai

178K

264K

Pelnas, tenkantis vienai akcijai

-0.257

Pelno marža

-6,603.409

Darbuotojai

116

EBITDA

2M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+34.41% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-179M

958M

Ankstesnė atidarymo kaina

22.21

Ankstesnė uždarymo kaina

22.57

Naujienos nuotaikos

By Acuity

26%

74%

49 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Pulse Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-17 22:42; UTC

Uždarbis

Prudential PLC 2025 Adjusted Operating Profit Rises

2026-03-17 21:40; UTC

Uždarbis

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

2026-03-17 23:56; UTC

Rinkos pokalbiai

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

2026-03-17 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After Recent Selloffs -- Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-17 23:42; UTC

Rinkos pokalbiai

RBA's Return to Policy Tightening Will Work -- Market Talk

2026-03-17 23:38; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-17 23:24; UTC

Rinkos pokalbiai

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

2026-03-17 22:22; UTC

Rinkos pokalbiai

BHP Hands Reins to Growth-Focused Executive -- Market Talk

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

2026-03-17 22:20; UTC

Uždarbis

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

2026-03-17 22:07; UTC

Uždarbis

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

2026-03-17 22:05; UTC

Uždarbis

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

2026-03-17 22:04; UTC

Uždarbis

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

2026-03-17 22:03; UTC

Uždarbis

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

2026-03-17 22:01; UTC

Uždarbis

ZTO Express (Cayman) 4Q EPS 47c >ZTO

2026-03-17 21:26; UTC

Uždarbis

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

2026-03-17 21:09; UTC

Uždarbis

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

2026-03-17 21:08; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:07; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:06; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Rev $21.8B >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q EPS 82c >ATD.T

2026-03-17 21:05; UTC

Uždarbis

Couche-Tard 3Q Net $757.2M >ATD.T

2026-03-17 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Pulse Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

34.41% į viršų

12 mėnesių prognozė

Vidutinis 30 USD  34.41%

Aukščiausias 30 USD

Žemiausias 30 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pulse Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

16.59 / 17.17Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

49 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
help-icon Live chat